Pfizer seeks label expansion for Litfulo after double Phase III NSV win

Phase 3positiveLitfuloPositive

AI Analysis

Summary

Pfizer announced positive Phase III results from the TRANQUILLO programme for Litfulo in nonscarring alopecia, positioning the drug for potential label expansion beyond its current approval in alopecia areata.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Double Phase III win in nonscarring alopecia (NSV) with TRANQUILLO programme

Importance:7/10

Sentiment:

0.80

label_expansionPhase_3_successalopecia_areataregulatory

Related Companies

$PFE

Read the original article

Published by Clinical Trials Arena on July 30, 2026 3:33 PM

Read Original